Ilmn morningstar rating add to portfolio get email alerts print this page pdf report data question quote chart stock analysis. Illumina reports financial results for fourth quarter and fiscal year 2019. We are dedicated to improving human health by unlocking the power of the genome. Headquarter relocation for fiscal 2012 and fiscal 2011 consisted of ceaseuse.
Our earnings reports, supplementary data, 10q and 10k, and selected other documents are available below by quarter. Illumina investor relations source book april 2019 2 this source book is intended to pull together information to help you learn about illumina s product offering, strategy and historic performance. Illumina incilmn annual report 10k quarterly report 10q. Click the button below to request a report when hardcopies become available. Annual reports investor relations incyte corporation. Find out the revenue, expenses and profit or loss over the last fiscal year. Get the latest full company report for illumina inc from zacks investment research. Illumina reports full financial results for fourth quarter. Shares of the genomic sequencing company were down 17% year to date. This annual report on form 10k contains forwardlooking statements. Beginning at the genetic level, illumina tools are used to elucidate the.
Companys projected annual instrument utilization 3. Ilmn sec filing 10k annual report for the fiscal year ending sunday, december 29, 2019. Looking ahead illumina also confirmed guidance for the 2015 fiscal year that was initially provided during the jp morgan conference. Tb equivalent to 16 human genomes of genomic data in a single run. Illumina reports financial results for third quarter of. A global leader in dna sequencing and arraybased technologies, illumina is fueling. Ilmn today announced its financial results for the third quarter of fiscal year 2015.
Export annual and quarterly reports to adobe pdf, microsoft word and excel for offline viewing, annotations and analysis. This annual report on form 10k contains, and our officers and. In 2015 we published the paper that accompanies the neurox genotyping array, a tool that was born from the collaborative efforts of several dozen researchers and illumina. A global leader in dna sequencing and arraybased technologies, illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. Get the detailed quarterlyannual income statement for illumina, inc. As of january 16, 2020, we owned or had exclusive licenses to 799. Illumina reports financial results for first quarter of fiscal year 2020. Illumina reports financial results for first quarter of. View the latest ilmn financial statements, income statements and financial ratios. Annual report pursuant to section or 15d of the securities. Section 16a beneficial ownership reporting compliance. View all ilmn assets, cash, debt, liabilities, shareholder equity and investments. The company expects revenue growth of 20% and nongaap earnings. In 2015, we continued to increase our manufacturing capacity to meet customer demand.